MOST COMMON NON-OPIOID MEDICINES ...
MOST COMMON NON-OPIOID MEDICINES ...
1. SIMPLE ANALGESICS
Acetaminophen — 650 mg q4–6h PO (max 4g/day). FDA: mild-moderate pain. Off-label: OA adjunct. Common: nausea. Serious: hepatotoxicity. [1]
2. ORAL NSAIDs
Aspirin — 325–650 mg q4h PO (max 3.6g/day). FDA: mild pain, rheumatic disease. Off-label: anti-platelet. Common: dyspepsia. Serious: GI bleeding, Reye syndrome. [1]
Ibuprofen — 200–800 mg q6–8h (max 3.2g/day). FDA: pain, OA, RA. Off-label: renal colic. Common: dyspepsia. Serious: GI bleed, MI/stroke, AKI. [1-2]
Naproxen — 250–500 mg q12h (max 1.25g/day). FDA: pain, OA, RA. Off-label: gout flare. Common: nausea. Serious: GI bleed, CV events. [1-2]
Celecoxib — 100–200 mg daily-BID. FDA: OA, RA, acute pain. Off-label: FAP. Common: edema. Serious: CV events, GI bleed. [2]
Ketorolac — 10 mg PO q6h or 30 mg IV (max 5 days). FDA: acute moderate-severe pain. Off-label: renal colic. Common: dyspepsia. Serious: GI bleed, renal failure. [3]
Diclofenac — 50 mg PO TID or 1% gel topical. FDA: OA, acute pain. Off-label: migraine. Common: nausea. Serious: GI bleed, hepatotoxicity. [2][4]
Meloxicam — 7.5–15 mg daily. FDA: OA, RA. Off-label: ankylosing spondylitis. Common: dyspepsia. Serious: GI bleed, CV events. [2]
3. TOPICAL ANALGESICS
Diclofenac gel 1% — 2–4 g QID topically (max 32g/day). FDA: OA. Off-label: tendinopathy. Common: site irritation. Serious: rare systemic NSAID effects. [2][5]
Lidocaine 5% patch — 1–3 patches up to 12h/day. FDA: postherpetic neuralgia. Off-label: myofascial pain, OA. Common: site erythema. Serious: rare systemic toxicity. [1][6]
Capsaicin 8% patch — 1–4 patches q3 months (applied 30–60 min). FDA: PHN, DPN. Off-label: other neuropathies. Common: site pain/burning. Serious: hypertension, reduced sensation. [1][6]
4. ANTIDEPRESSANTS (ANALGESIC)
Duloxetine — 60–120 mg daily. FDA: DPN, fibromyalgia, chronic MSK pain. Off-label: OA, low back pain. Common: nausea. Serious: suicidality, serotonin syndrome. [1-2]
Amitriptyline — 25–150 mg daily. FDA: depression. Off-label: neuropathic pain, migraine prophylaxis. Common: dry mouth, sedation. Serious: cardiac arrhythmia, suicidality. [1][7]
Nortriptyline — 10–150 mg daily. FDA: depression. Off-label: neuropathic pain, headache prophylaxis. Common: constipation, sedation. Serious: cardiac arrhythmia. [7-8]
Venlafaxine — 150–225 mg daily. FDA: depression/anxiety. Off-label: neuropathic pain, migraine prophylaxis. Common: nausea, sweating. Serious: hypertension, serotonin syndrome. [2][7]
Milnacipran — 50 mg BID (max 200 mg/day). FDA: fibromyalgia. Off-label: MSK pain. Common: nausea, headache. Serious: hypertension, suicidality. [2]
5. ANTICONVULSANTS (GABAPENTINOIDS)
Gabapentin — 900–3600 mg/day in 3 divided doses. FDA: postherpetic neuralgia. Off-label: radiculopathy, perioperative pain. Common: dizziness, sedation. Serious: respiratory depression (with CNS depressants), misuse. [1][7]
Pregabalin — 300–600 mg/day in 2 divided doses. FDA: DPN, PHN, SCI pain, fibromyalgia. Off-label: radiculopathy, anxiety. Common: dizziness, weight gain. Serious: angioedema, misuse/dependence. [1][7]
6. MUSCLE RELAXANTS
Cyclobenzaprine — 5–10 mg TID. FDA: acute muscle spasm. Off-label: fibromyalgia. Common: drowsiness, dry mouth. Serious: arrhythmia, serotonin syndrome. [2]
Baclofen — 5–10 mg TID (max 80 mg/day). FDA: spasticity. Off-label: low back pain. Common: drowsiness, dizziness. Serious: withdrawal seizures. [2]
Tizanidine — 2–4 mg q8–12h (max 36 mg/day). FDA: spasticity. Off-label: low back pain. Common: somnolence, dry mouth. Serious: hepatotoxicity, hypotension. [2]
Methocarbamol — 1500 mg QID then 750 mg QID. FDA: acute muscle spasm. Off-label: chronic back pain. Common: drowsiness, dizziness. Serious: seizures (rare), CNS depression. [2]
7. OTHER AGENTS (NMDA ANTAGONISTS / CORTICOSTEROIDS)
Ketamine (sub-dissociative) — 0.1–0.3 mg/kg IV. FDA: anesthesia. Off-label: acute/chronic pain, CRPS. Common: dysphoria, dizziness. Serious: laryngospasm, psychotomimetic effects. [3][9]
Dexamethasone — 4–10 mg IV/PO (dose varies). FDA: inflammation. Off-label: radiculopathy, postop pain. Common: hyperglycemia, insomnia. Serious: immunosuppression, AVN. [3][7]
Magnesium sulfate — 30–50 mg/kg IV bolus ± infusion. FDA: eclampsia/hypomagnesemia. Off-label: perioperative pain, migraine. Common: flushing, hypotension. Serious: respiratory depression, hypermagnesemia. [10-11]
8. CANNABINOIDS
No FDA-approved cannabinoid carries a pain indication; all pain use is off-label. The ACP (2025) recommends against cannabinoids as first-line for chronic pain. [12][15]
Dronabinol (synthetic THC) — 2.5–10 mg BID-TID PO. FDA: CINV, HIV anorexia. Off-label: neuropathic/chronic pain. Common: euphoria, dizziness, somnolence. Serious: psychosis, dependence. Schedule II/III. [12][14]
Nabilone — 1–2 mg BID PO (max 6 mg/day). FDA: CINV. Off-label: neuropathic pain, fibromyalgia. Common: vertigo (52%), drowsiness (52%), dry mouth. Serious: dysphoria, dependence. Schedule II.
[12][14]
Cannabidiol (Epidiolex) — 2.5 mg/kg BID PO (max 20 mg/kg/day). FDA: Dravet/LGS/TSC seizures. Off-label: chronic pain (limited evidence). Common: diarrhea, somnolence. Serious: hepatotoxicity (↑ALT/AST).
[4][12]
Nabiximols (Sativex) — 1:1 THC:CBD oromucosal spray, titrate 1–12 sprays/day. Not FDA-approved (approved in UK/EU). Off-label: MS spasticity, neuropathic pain. Common: dizziness, nausea. Serious: falls, cognitive impairment.
[12][15]
9. MIGRAINE-SPECIFIC ANALGESICS (TRIPTANS, GEPANTS, DITANS)
[16-18]
Sumatriptan — 25–100 mg PO or 6 mg SC. FDA: acute migraine, cluster headache. Off-label: post-dural puncture headache. Common: flushing, chest tightness. Serious: coronary vasospasm, serotonin syndrome.
[16]
Rizatriptan — 5–10 mg PO (ODT available). FDA: acute migraine. Off-label: menstrual migraine. Common: dizziness, fatigue. Serious: coronary vasospasm.
[16]
Eletriptan — 20–40 mg PO (may repeat ×1). FDA: acute migraine. Off-label: menstrual migraine. Common: somnolence, nausea. Serious: coronary vasospasm.
[16]
Ubrogepant (Ubrelvy) — 50–100 mg PO. FDA: acute migraine. Off-label: none established. Common: nausea, somnolence. Serious: rare hepatotoxicity.
[4][19]
Rimegepant (Nurtec) — 75 mg PO/ODT. FDA: acute migraine + migraine prevention. Off-label: none established. Common: nausea. Serious: hypersensitivity (rare).
[19-20]
Atogepant (Qulipta) — 10–60 mg daily PO. FDA: migraine prevention. Off-label: none established. Common: constipation, nausea. Serious: hepatotoxicity (rare).
[4]
Lasmiditan (Reyvow) — 50–200 mg PO. FDA: acute migraine. Off-label: none established. Common: dizziness, sedation. Serious: driving impairment (8h restriction), serotonin syndrome.
[16][19]
10. CGRP MONOCLONAL ANTIBODIES (MIGRAINE PREVENTION)
[4][21]
Erenumab (Aimovig) — 70–140 mg SC monthly. FDA: migraine prevention. Off-label: cluster headache. Common: injection site reactions, constipation. Serious: hypertension, severe constipation.
[4]
Galcanezumab (Emgality) — 240 mg loading then 120 mg SC monthly. FDA: migraine prevention, episodic cluster headache. Off-label: none established. Common: injection site reactions. Serious: hypersensitivity (rare).
[4]
Fremanezumab (Ajovy) — 225 mg SC monthly or 675 mg quarterly. FDA: migraine prevention. Off-label: none established. Common: injection site reactions. Serious: hypersensitivity (rare).
[4]
Eptinezumab (Vyepti) — 100–300 mg IV q3 months. FDA: migraine prevention. Off-label: none established. Common: nasopharyngitis, fatigue. Serious: anaphylaxis (rare).
[4]
11. BONE-TARGETED ANALGESICS
[22-24]
Zoledronic acid — 4 mg IV over 15 min q3–4 weeks. FDA: bone metastases, Paget disease. Off-label: metastatic bone pain. Common: acute-phase reaction, fever. Serious: ONJ, renal toxicity, AFF.
[22][25]
Calcitonin (salmon) — 200 IU intranasal daily or 4–8 IU/kg SC/IM. FDA: osteoporosis, Paget disease. Off-label: acute VCF pain. Common: rhinitis, flushing. Serious: possible malignancy risk, hypocalcemia.
[23-24]
Denosumab (Xgeva) — 120 mg SC q4 weeks. FDA: bone metastases (SRE prevention), giant cell tumor. Off-label: metastatic bone pain. Common: fatigue, nausea. Serious: ONJ, hypocalcemia, AFF, rebound fractures on discontinuation.
[4][25]
1.
Lancet. 2024. GBD 2021 Diseases and Injuries Collaborators.
2.
Lancet. 2025. GBD 2023 Disease and Injury and Risk Factor Collaborators.
3.
Cardiovascular Research. 2024. López-Bueno R, Núñez-Cortés R, Calatayud J, et al.
4.
Global Burden of Metabolic Diseases, 1990-2021.
Metabolism: Clinical and Experimental. 2024. Zhang H, Zhou XD, Shapiro MD, et al.
5.
EClinicalMedicine. 2023. GBD 2019 Chronic Respiratory Diseases Collaborators.
6.
Nature Medicine. 2026. Oh J, Kim S, Yim Y, et al.New
7.
The Lancet. Respiratory Medicine. 2017. GBD 2015 Chronic Respiratory Disease Collaborators.
8.
PloS One. 2017. Harrison C, Henderson J, Miller G, Britt H.
9.
Prevalence of Chronic Conditions in Australia.
PloS One. 2013. Harrison C, Britt H, Miller G, Henderson J.
10.
Lancet. 2025. Kloppenburg M, Namane M, Cicuttini F.
11.
Epidemiology of Risk Factors for Osteoarthritis: Systemic Factors.
Current Opinion in Rheumatology. 2001. Sowers M.
12.
The Journal of the American Medical Association. 2023. Aggarwal R, Yeh RW, Joynt Maddox KE, Wadhera RK.
13.
Journal of Psychosomatic Research. 2023. Aw PY, Pang XZ, Wee CF, et al.
14.
Understanding the Drivers and Consequences of Early-Onset Type 2 Diabetes.
Lancet. 2025. Lim LL, Jones S, Cikomola JC, Hivert MF, Misra S.New
15.
Neuroscience and Biobehavioral Reviews. 2023. Possidente C, Fanelli G, Serretti A, Fabbri C.
16.
Diabetes Care. 2022. Liu S, Leone M, Ludvigsson JF, et al.
17.
Circulation. 2021. Levine GN, Cohen BE, Commodore-Mensah Y, et al.Guideline
18.
Meta-Analysis of Anxiety as a Risk Factor for Cardiovascular Disease.
The American Journal of Cardiology. 2016. Emdin CA, Odutayo A, Wong CX, et al.
19.
ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.
The American Journal of Gastroenterology. 2022. Katz PO, Dunbar KB, Schnoll-Sussman FH, et al.Guideline
20.
American Journal of Respiratory and Critical Care Medicine. 2001. Theodoropoulos DS, Ledford DK, Lockey RF, et al.
21.
What Are the Most Common Conditions in Primary Care? Systematic Review.
Canadian Family Physician Medecin De Famille Canadien. 2018. Finley CR, Chan DS, Garrison S, et al.
22.
BMC Medical Informatics and Decision Making. 2023. Cooper J, Nirantharakumar K, Crowe F, et al.
23.
Global Burden of Chronic Respiratory Diseases.
Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2020. Viegi G, Maio S, Fasola S, Baldacci S.
Natural treatment options for the top 20 most common medical conditions where applicable:
Based on the comprehensive evidence available, here are natural treatment options for the top 20 most common medical conditions where applicable:
[1-49]
1. 💓 Hypertension
Natural Options: DASH diet (fruits, vegetables, low-fat dairy, reduced sodium), Mediterranean diet, potassium-rich foods, weight loss (1 mm Hg per kg lost), regular aerobic exercise (150 min/week), stress reduction techniques, limit alcohol to ≤1-2 drinks/day
[1-3]
2. 🦴 Osteoarthritis
Natural Options: Weight loss (5-20% body weight), exercise (aerobic, strengthening, aquatic), tai chi, yoga, physical therapy, heat/cold therapy, acupuncture, massage/myofascial release, glucosamine/chondroitin (mixed evidence)
[4-7]
3. 💊 Hyperlipidemia
Natural Options: Mediterranean diet, vegetarian/vegan diet (lowers LDL 11.6 mg/dL), plant-based proteins, nuts (one serving daily lowers LDL 4.8 mg/dL), oat fiber, plant sterols, omega-3 fatty acids, avoid saturated fats, replace with unsaturated fats, weight loss, regular exercise
[8-10]
4. 😔 Depression
Natural Options: Omega-3 fatty acids (EPA/DHA), SAMe (S-adenosylmethionine), St. John's wort (mild-moderate depression), saffron, curcumin, vitamin D, folate/methylfolate, regular exercise (aerobic training), cognitive behavioral therapy, mindfulness meditation, light therapy, adequate sleep
[11-16]
5. 🍬 Type 2 Diabetes
Natural Options: Weight loss (7-10% body weight), 150 min/week moderate exercise, Mediterranean diet, low-glycemic index foods, DASH diet, plant-based diets, limit processed carbohydrates, medical nutrition therapy, stress management, adequate sleep
[17-20]
6. 😰 Anxiety Disorders
Natural Options: Lavender extract (Silexan), chamomile, ashwagandha, kava kava, passionflower, lemon balm, magnesium, omega-3 fatty acids, regular exercise, yoga, mindfulness-based stress reduction, cognitive behavioral therapy, adequate sleep
[21-26]
7. 🔥 GERD
Natural Options: Weight loss, elevate head of bed 6-8 inches, avoid eating 3 hours before bedtime, sleep on left side, avoid trigger foods (caffeine, alcohol, chocolate, spicy/fatty foods, peppermint), smaller meals, smoking cessation, stress reduction, chewing gum to promote salivation
[27-29]
8. 🫁 Asthma
Natural Options: Avoid allergens and triggers, breathing exercises (Buteyko, Papworth method), regular physical activity, maintain healthy weight, Mediterranean diet rich in fruits/vegetables, omega-3 fatty acids, antioxidant-rich foods, vitamin D, smoking cessation, reduce air pollution exposure
[30-35]
9. 🤕 Low Back Pain
Natural Options: Exercise (aerobic, strengthening, stretching), yoga, tai chi, physical therapy, cognitive behavioral therapy, mindfulness-based stress reduction, spinal manipulation, acupuncture, massage therapy, heat/cold therapy, maintain healthy weight, proper posture and ergonomics
[48-49]
10. 🤧 Upper Respiratory Infections
Natural Options: Hand hygiene, adequate hydration, rest, vitamin C, zinc lozenges (within 24 hours of symptom onset), honey for cough, humidified air, saline nasal rinses, echinacea (mixed evidence), adequate sleep, stress management
11. 🧠 Stroke
Natural Options: Prevention focus: Mediterranean diet, DASH diet, regular exercise (150 min/week), maintain healthy weight, smoking cessation, limit alcohol, stress management, adequate sleep, control blood pressure naturally (see hypertension)
12. ❤️ Ischemic Heart Disease
Natural Options: Mediterranean diet, omega-3 fatty acids (fatty fish 2x/week), plant-based diet, regular aerobic exercise, weight management, smoking cessation, stress reduction (meditation, yoga), adequate sleep, limit alcohol, nuts and seeds
13. 🫁 COPD
Natural Options: Smoking cessation (most important), pulmonary rehabilitation, breathing exercises, regular physical activity, adequate nutrition, avoid air pollutants, stay hydrated, energy conservation techniques, pursed-lip breathing
14. 🤕 Headache Disorders
Natural Options: Magnesium (400-600 mg/day), riboflavin/vitamin B2 (400 mg/day), feverfew, CoQ10 (100-300 mg/day), melatonin, regular sleep schedule, stress management, adequate hydration, identify and avoid triggers, regular exercise, acupuncture, biofeedback, mindfulness meditation
[36-41]
15. 🦷 Oral Disorders
Natural Options: Regular brushing (2x/day with fluoride), flossing daily, limit sugar intake, xylitol gum, oil pulling (limited evidence), green tea (antimicrobial properties), adequate calcium and vitamin D, crunchy fruits/vegetables, stay hydrated
16. 💧 Diarrheal Diseases
Natural Options: Oral rehydration solution, probiotics, zinc supplementation (especially children), BRAT diet initially (bananas, rice, applesauce, toast), avoid dairy temporarily, ginger tea, chamomile tea, adequate hydration, hand hygiene
17. 🦟 Lower Respiratory Infections
Natural Options: Vaccination (pneumococcal, influenza), adequate hydration, rest, honey for cough, humidified air, vitamin C, vitamin D, zinc, probiotics, adequate nutrition, hand hygiene, avoid smoking
18. 🩸 Anemia
Natural Options: Iron-rich foods (red meat, spinach, lentils, fortified cereals), vitamin C with iron to enhance absorption, vitamin B12 sources (animal products, fortified foods), folate-rich foods (leafy greens, legumes), avoid tea/coffee with meals (inhibits iron absorption), cook in cast iron
19. 🧬 Neonatal Disorders
Natural Options: Prenatal care, adequate maternal nutrition, folic acid supplementation (400-800 mcg/day), avoid alcohol/tobacco/drugs, manage maternal chronic conditions, breastfeeding support, skin-to-skin contact, adequate maternal rest
20. 🦴 Musculoskeletal Pain
Natural Options: Regular exercise (low-impact aerobic, strengthening), yoga, tai chi, physical therapy, heat/cold therapy, massage, acupuncture, maintain healthy weight, proper ergonomics, adequate sleep, stress management, turmeric/curcumin, omega-3 fatty acids
[48-49]
Additional Natural Options for Sleep/Insomnia (relevant for multiple conditions):
Melatonin (0.5-5 mg), valerian root, magnesium, chamomile tea, lavender aromatherapy, sleep hygiene (consistent schedule, dark/cool room), limit screen time before bed, relaxation techniques, cognitive behavioral therapy for insomnia
[42-47]
Important Considerations:
Natural treatments work best when combined with conventional care, not as replacements for necessary medications
Quality and dosing of supplements vary; choose pharmaceutical-grade products when possible
Consult healthcare providers before starting supplements, especially if taking medications
Lifestyle modifications (diet, exercise, stress management, sleep) form the foundation of natural approaches
Evidence quality varies; some interventions have strong support while others need more research
Individual responses vary; what works for one person may not work for another
Would you like me to provide more detailed protocols or specific dosing information for any particular condition or natural treatment?
1.
Diagnosis and Management of Hypertension (HTN) in Primary Care (2020).
Department of Veterans Affairs. 2020. Angela A. Allerman PharmD BPCS, Jennifer Ballard-Hernandez DNP NP CCRN, Dan Berlowitz MD MPH, et alGuideline
2.
Treatment of Hypertension: A Review.
The Journal of the American Medical Association. 2022. Carey RM, Moran AE, Whelton PK.
3.
The New England Journal of Medicine. 2024. Yannakoulia M, Scarmeas N.
4.
Arthritis & Rheumatology. 2020. Kolasinski SL, Neogi T, Hochberg MC, et al.Guideline
5.
Diagnosis and Treatment of Hip and Knee Osteoarthritis: A Review.
The Journal of the American Medical Association. 2021. Katz JN, Arant KR, Loeser RF.
6.
American Family Physician. 2021. Buelt A, Narducci DM.Guideline
7.
The New England Journal of Medicine. 2021. Sharma L.
8.
Journal of the American College of Cardiology. 2026. Blumenthal RS, Morris PB, Gaudino M, et al.NewGuideline
9.
Circulation. 2026. Writing Committee Members, Blumenthal RS, Morris PB, et al.NewGuideline
10.
Reprint Of: Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series.
Journal of the American College of Cardiology. 2018. Ference BA, Graham I, Tokgozoglu L, Catapano AL.
11.
Psychological Medicine. 2025. Cheng YC, Huang WL, Chen WY, et al.New
12.
Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses.
The American Journal of Psychiatry. 2016. Sarris J, Murphy J, Mischoulon D, et al.
13.
Clinical Nutrition. 2025. Raza ML, Hassan ST, Jamil S, Fatima W, Fatima M.
14.
Frontiers in Pharmacology. 2025. Frost R, Zamri A, Mathew S, et al.
15.
The Cochrane Database of Systematic Reviews. 2013. Dennis CL, Dowswell T.
16.
Management of Depression in Adults: A Review.
The Journal of the American Medical Association. 2024. Simon GE, Moise N, Mohr DC.
17.
3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2026.
Diabetes Care. 2026. American Diabetes Association Professional Practice Committee for Diabetes*.NewGuideline
18.
American Family Physician. 2022. Rey JB, Hawks M.Guideline
19.
Lancet. 2022. Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ.
20.
Diabetes Care. 2022. Davies MJ, Aroda VR, Collins BS, et al.Guideline
21.
Generalized Anxiety Disorder and Panic Disorder in Adults.
American Family Physician. 2022. DeGeorge KC, Grover M, Streeter GS.
22.
Medicinal Herbs for the Treatment of Anxiety: A Systematic Review and Network Meta-Analysis.
Pharmacological Research. 2022. Zhang W, Yan Y, Wu Y, et al.
23.
Nip It in the Bud: Botanicals for Anxiety - A Practical Prescriber's Guide.
Current Psychiatry Reports. 2022. Gattari TB, Drake K, Scott A.
24.
The Journal of the American Medical Association. 2022. Szuhany KL, Simon NM.
25.
Phytotherapy Research : PTR. 2018. Yeung KS, Hernandez M, Mao JJ, Haviland I, Gubili J.
26.
Herbal Medicines in the Treatment of Psychiatric Disorders: 10-Year Updated Review.
Phytotherapy Research : PTR. 2018. Sarris J.
27.
ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.
The American Journal of Gastroenterology. 2022. Katz PO, Dunbar KB, Schnoll-Sussman FH, et al.Guideline
28.
Gastroesophageal Reflux Disease.
The New England Journal of Medicine. 2022. Fass R.
29.
Journal of the American Geriatrics Society. 2025. Steinman MA.NewGuideline
30.
Basis of Preventive and Non-Pharmacological Interventions in Asthma.
Frontiers in Public Health. 2023. Clemente-Suárez VJ, Mielgo-Ayuso J, Ramos-Campo DJ, et al.
31.
Mechanism of Action of Certain Medicinal Plants for the Treatment of Asthma.
Journal of Ethnopharmacology. 2023. Usmani K, Jain SK, Yadav S.
32.
Use of Natural Products in Asthma Treatment.
Evidence-Based Complementary and Alternative Medicine : eCAM. 2020. Amaral-Machado L, Oliveira WN, Moreira-Oliveira SS, et al.
33.
Breathing Exercises for Children With Asthma.
The Cochrane Database of Systematic Reviews. 2016. Macêdo TM, Freitas DA, Chaves GS, Holloway EA, Mendonça KM.
34.
Breathing Exercises for Asthma.
The Cochrane Database of Systematic Reviews. 2000. Holloway E, Ram FS.
35.
An Overview of Integrative Therapies in Asthma Treatment.
Current Allergy and Asthma Reports. 2014. McClafferty H.
36.
Complementary and Integrative Medicine in the Management of Headache.
BMJ. 2017. Millstine D, Chen CY, Bauer B.
37.
Migraine Headache Prophylaxis.
American Family Physician. 2025. Moreland P, Gaffney B, Lanham JS.New
38.
Current Pain and Headache Reports. 2025. Tepper SJ, Tepper K.
39.
Herbal Treatments for Migraine: A Systematic Review of Randomised-Controlled Studies.
Phytotherapy Research : PTR. 2020. Lopresti AL, Smith SJ, Drummond PD.
40.
International Journal of Environmental Research and Public Health. 2021. Grazzi L, Toppo C, D'Amico D, et al.
41.
Current Pain and Headache Reports. 2019. Wells RE, Beuthin J, Granetzke L.
42.
Dietary Protocols to Promote and Improve Restful Sleep: A Narrative Review.
Nutrition Reviews. 2026. Conti F.New
43.
Complementary and Alternative Treatments for Insomnia Disorder: A Systematic Umbrella Review.
Journal of Sleep Research. 2023. Ell J, Schmid SR, Benz F, Spille L.
44.
Therapeutic Potential of Hypnotic Herbal Medicines: A Comprehensive Review.
Phytotherapy Research : PTR. 2024. Ghasemzadeh Rahbardar M, Hosseinzadeh H.
45.
Over-the-Counter Products for Insomnia in Adults: A Scoping Review of Randomised Controlled Trials.
Sleep Medicine. 2025. Salame A, Mathew S, Bhanu C, et al.New
46.
Integrative Sleep Management: From Molecular Pathways to Conventional and Herbal Treatments.
Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. Ebrahim YM, Sadek MA, Sabry MO, et al.New
47.
Non-Pharmacologic Treatment of Insomnia in Primary Care Settings.
International Journal of Clinical Practice. 2021. Hrehová L, Mezian K.
48.
CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022.
MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2022. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R.Guideline
49.
Chronic Musculoskeletal Pain: Nonpharmacologic, Noninvasive Treatments.
American Family Physician. 2020. Flynn DM.